NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Forecast, Price & News $15.93 -0.78 (-4.67%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$15.65▼$16.7250-Day Range$15.84▼$22.0152-Week Range$11.13▼$30.79Volume51,267 shsAverage Volume88,206 shsMarket Capitalization$395.22 millionP/E RatioN/ADividend YieldN/APrice Target$39.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aerovate Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Downside$0.00 Price TargetShort InterestBearish5.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.42 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.75) to ($2.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.55 out of 5 starsMedical Sector794th out of 985 stocksPharmaceutical Preparations Industry394th out of 481 stocks 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $0.00, Aerovate Therapeutics has a forecasted downside of 100.0% from its current price of $15.93.Amount of Analyst CoverageAerovate Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.93% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Aerovate Therapeutics has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTE. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for AVTE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,418,383.00 in company stock.Percentage Held by Insiders17.80% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -6.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -6.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aerovate Therapeutics (NASDAQ:AVTE) StockAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTE Stock News HeadlinesMay 23, 2023 | msn.comPeter Kolchinsky-led RA Capital’s New Positions Feature CureVac, Mineralys, Pilant, Enliven TherapeuticsMay 22, 2023 | finance.yahoo.comAerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International ConferenceJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 21, 2023 | americanbankingnews.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 1,090 Shares of StockMay 21, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.63) Per Share, Wedbush Forecasts (NASDAQ:AVTE)May 17, 2023 | markets.businessinsider.comAerovate Therapeutics (AVTE) Receives a Buy from WedbushMay 16, 2023 | msn.comAerovate Therapeutics GAAP EPS of -$0.67 misses by $0.07May 16, 2023 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 15, 2023 | msn.comRecap: Aerovate Therapeutics Q1 EarningsMay 15, 2023 | finance.yahoo.comAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsMay 15, 2023 | finance.yahoo.comAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsMay 11, 2023 | americanbankingnews.comBenjamin T. Dake Sells 10,284 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMay 10, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Ralph Niven Sells 2,250 Shares of StockMay 4, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Timothy P. Noyes Sells 15,000 SharesMay 3, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Large Increase in Short InterestApril 28, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $78,000.00 in StockApril 12, 2023 | seekingalpha.comAerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH MarketApril 8, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 10,283 Shares of StockApril 6, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Timothy P. Noyes Sells 15,000 Shares of StockApril 5, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Issued By WedbushMarch 31, 2023 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) to Post FY2027 Earnings of $2.16 Per Share, Wedbush ForecastsMarch 30, 2023 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business HighlightsMarch 29, 2023 | finance.yahoo.comAerovate Therapeutics Announces Full-Year 2022 Financial Results and Business HighlightsMarch 24, 2023 | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Trading Down 5.3%March 9, 2023 | benzinga.comAerovate Therapeutics Chief Executive Officer Awarded $3.29M Worth of Stock OptionsMarch 3, 2023 | msn.comGuggenheim Initiates Coverage of Aerovate Therapeutics (AVTE) with Buy RecommendationSee More Headlines AVTE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTE Company Calendar Last Earnings3/29/2023Today6/05/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Forecast$39.00 High Stock Price Forecast$54.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+144.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.11% Return on Assets-40.58% Debt Debt-to-Equity RatioN/A Current Ratio11.34 Quick Ratio11.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book3.07Miscellaneous Outstanding Shares24,810,000Free Float20,394,000Market Cap$395.22 million OptionableNot Optionable Beta0.33 Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 61)CEO & Director Comp: $655.65kDr. Benjamin T. Dake Ph.D. (Age 47)Founder, Pres, COO & Sec. Comp: $435.5kMr. George A. Eldridge (Age 60)CFO & Treasurer Comp: $454.64kMr. Hunter Gillies M.D. (Age 57)Chief Medical Officer Comp: $512.74kDr. Ralph W. Niven M.B.A. (Age 63)M.R, Ph.D., Pharm.S, Chief Scientific Officer Mr. Timothy J. PigotSr. VP of CommercialMs. Donna DeaHead of Regulatory AffairsDr. Marinus Verwijs Ph.D. (Age 47)Sr. VP of CMC Ms. Susan FischerSr. VP of Devel. OperationsMr. Stephen YuSr. VP of QualityMore ExecutivesKey CompetitorsErascaNASDAQ:ERASSIGA TechnologiesNASDAQ:SIGAArbutus BiopharmaNASDAQ:ABUSPepGenNASDAQ:PEPGAllakosNASDAQ:ALLKView All CompetitorsInsiders & InstitutionsGolden State Equity PartnersBought 10,530 shares on 6/1/2023Ownership: 0.042%Hunter GilliesSold 65 sharesTotal: $1,267.50 ($19.50/share)JPMorgan Chase & Co.Bought 1,817 shares on 5/18/2023Ownership: 0.029%Hunter GilliesSold 1,090 sharesTotal: $21,353.10 ($19.59/share)Baker BROS. Advisors LPSold 13,389 shares on 5/16/2023Ownership: 7.914%View All Insider TransactionsView All Institutional Transactions AVTE Stock - Frequently Asked Questions Should I buy or sell Aerovate Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVTE shares. View AVTE analyst ratings or view top-rated stocks. What is Aerovate Therapeutics' stock price forecast for 2023? 3 Wall Street analysts have issued 12 month price targets for Aerovate Therapeutics' shares. Their AVTE share price forecasts range from $27.00 to $54.00. On average, they expect the company's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 144.8% from the stock's current price. View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts. How have AVTE shares performed in 2023? Aerovate Therapeutics' stock was trading at $29.30 at the start of the year. Since then, AVTE stock has decreased by 45.6% and is now trading at $15.93. View the best growth stocks for 2023 here. Are investors shorting Aerovate Therapeutics? Aerovate Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 913,900 shares, a decrease of 5.3% from the April 30th total of 965,000 shares. Based on an average daily trading volume, of 72,700 shares, the days-to-cover ratio is presently 12.6 days. Approximately 5.9% of the shares of the stock are short sold. View Aerovate Therapeutics' Short Interest. When is Aerovate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our AVTE earnings forecast. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.03. What ETFs hold Aerovate Therapeutics' stock? ETFs with the largest weight of Aerovate Therapeutics (NASDAQ:AVTE) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), ALPS Medical Breakthroughs ETF (SBIO), When did Aerovate Therapeutics IPO? (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share. What is Aerovate Therapeutics' stock symbol? Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE." Who are Aerovate Therapeutics' major shareholders? Aerovate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (8.22%), Baker BROS. Advisors LP (7.91%), Great Point Partners LLC (3.05%), BlackRock Inc. (2.42%), FMR LLC (2.30%) and Ghost Tree Capital LLC (0.81%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aerovate Therapeutics' stock price today? One share of AVTE stock can currently be purchased for approximately $15.93. How much money does Aerovate Therapeutics make? Aerovate Therapeutics (NASDAQ:AVTE) has a market capitalization of $395.22 million. The company earns $-51,510,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. How can I contact Aerovate Therapeutics? The official website for the company is aerovatetx.com. The company can be reached via phone at 617-443-2400 or via email at ir@aerovatetx.com. This page (NASDAQ:AVTE) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.